coin-img-BTCBTC-0.07%coin-img-ETHETH+0.25%coin-img-SOLSOL-1.24%coin-img-XRPXRP-0.57%coin-img-USDCUSDC+0.04%coin-img-HYPEHYPE-2.62%coin-img-LABLAB-27.54%coin-img-TRXTRX-1.63%coin-img-BTCBTC-0.07%coin-img-ETHETH+0.25%coin-img-SOLSOL-1.24%coin-img-XRPXRP-0.57%coin-img-USDCUSDC+0.04%coin-img-HYPEHYPE-2.62%coin-img-LABLAB-27.54%coin-img-TRXTRX-1.63%coin-img-BTCBTC-0.07%coin-img-ETHETH+0.25%coin-img-SOLSOL-1.24%coin-img-XRPXRP-0.57%coin-img-USDCUSDC+0.04%coin-img-HYPEHYPE-2.62%coin-img-LABLAB-27.54%coin-img-TRXTRX-1.63%coin-img-BTCBTC-0.07%coin-img-ETHETH+0.25%coin-img-SOLSOL-1.24%coin-img-XRPXRP-0.57%coin-img-USDCUSDC+0.04%coin-img-HYPEHYPE-2.62%coin-img-LABLAB-27.54%coin-img-TRXTRX-1.63%
user-avatar
CNBC TV18

Alembic Pharma shares slide 2% after USFDA warning letter tied to Vadodara bioequivalence facility

AI Market Summary
Alembic Pharma shares fell after the USFDA issued a warning letter tied to a clinical investigator involved in a Vadodara bioequivalence study, citing informed consent form deficiencies. While the company says there are no data integrity issues, no operational restrictions, and no material financial impact yet, the event raises regulatory overhang risk and could slow ANDA review timelines, pressuring sentiment around US-facing generic drug pipeline execution.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.85%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The US Food and Drug Administration issued a warning letter dated July 10, 2026, to a clinical investigator linked to a bioequivalence study conducted at Alembic Pharma’s Vadodara facility. The letter followed an inspection conducted between March 3 and March 7, 2025, and cited issues related to the Informed Consent Form used in the study. Alembic said the observations are not related to data integrity and that the warning letter does not restrict facility operations or have a material financial impact at this stage. The company said the matter could slow the review of its abbreviated new drug application (ANDA) submissions to the USFDA, raising investor concerns about export risks.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.